Related Experiment Video
Updated: Aug 30, 2026
Primary Microglia Isolation from Mixed Glial Cell Cultures of Neonatal Rat Brain Tissue
Published on: August 15, 2012
Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for
M-A Dommergues1, F Plaisant, C Verney
1INSERM E 9935, Service de Neurologie Pédiatrique, Hôpital Robert-Debré, 48 BD Sérurier, 75019 Paris, France.
Abstract:
Previous studies in a mouse model of neonatal excitotoxic brain damage mimicking the brain lesions in human cerebral palsy showed microglial activation within 24 h after intracerebral injection of the glutamatergic analog ibotenate. Using this model, we studied the expression of CD-45 antigen, a marker of blood-derived cells, by these activated microglial cells labeled by Griffonia simplicifolia I isolectin B4. Immunohistochemistry performed during early development of excitotoxic lesions showed that most cells labeled with the isolectin B4 were CD-45-negative, suggesting that these early activated microglial cells were deriving chiefly from resident microglia and not from circulating monocytes. We also directly tested the hypothesis that activated resident microglia and/or blood-derived monocytes play a role in the pathophysiology of excitotoxic brain damage. Repeated i.p. administrations of chloroquine, chloroquine+colchicine, minocycline, or an anti-MAC1 antibody coupled to the toxin saporin before and/or after ibotenate injection induced a significant reduction in the density of isolectin B4-positive cells. This inhibition of resident microglial and/or blood-derived monocytes activation was accompanied by a significant reduction in the severity of ibotenate-induced brain lesions (up to 79% lesion size reduction with the highest minocycline dose) as well as of ibotenate-induced cortical caspase-3 activation (49% reduction).
Insights
In neonatal brain injury models, resident microglia, not blood monocytes, are the primary responders. Inhibiting these cells significantly reduces brain damage and inflammation, offering potential therapeutic targets for cerebral palsy.
Area of Science:
- Neuroscience
- Immunology
- Developmental Biology
Background:
- Neonatal excitotoxic brain damage, a model for cerebral palsy, involves microglial activation.
- Microglia are key immune cells in the brain, and their activation is implicated in brain injury.
Purpose of the Study:
- To investigate the origin of activated microglia in neonatal excitotoxic brain damage.
- To determine the role of resident microglia and blood-derived monocytes in the pathophysiology of this brain injury model.
- To evaluate the therapeutic potential of inhibiting microglial activation.
Main Methods:
- Utilized a mouse model of neonatal excitotoxic brain damage induced by ibotenate.
- Employed immunohistochemistry with Griffonia simplicifolia I isolectin B4 and CD-45 antigen staining to identify microglial origin.
- Administered various inhibitors (chloroquine, minocycline, anti-MAC1 antibody) to assess their impact on microglial activation and lesion severity.
Main Results:
- Early activated microglial cells in the ibotenate model were predominantly CD-45-negative, indicating a resident microglia origin.
- Inhibition of microglial and/or monocyte activation significantly reduced the density of activated cells.
- Treatment with inhibitors led to a substantial reduction in lesion size (up to 79%) and cortical caspase-3 activation (49%).
Conclusions:
- Resident microglia, rather than circulating monocytes, are the primary immune cells activated in the early stages of neonatal excitotoxic brain injury.
- Targeting microglial activation presents a promising therapeutic strategy for mitigating brain damage and improving outcomes in conditions like cerebral palsy.
